The Washington Post Names Appian a 2017 "Top Workplace"
20.6.2017 14:00 | NASDAQ OMX
4th year in a row Application Platform leader has made the list
RESTON, Va., June 20, 2017 (GLOBE NEWSWIRE) -- Appian (NASDAQ:APPN) today announces that it has been named to the The Washington Post's "2017 Top Workplaces" list. This is the fourth year that the list has been published, and the fourth time that Appian has been named a winner. In the new list, Appian was cited for sustaining a dynamic environment that keeps employees engaged, where debate is encouraged across all levels of the company, and where every employee is empowered to try new ideas and approaches in pursuit of positive results.
In its fourth survey, The Washington Post's Top Workplaces list spotlights private, public, nonprofit and government agencies with the highest ratings from their employees in a survey conducted by Workplace Dynamics. The Washington Post invited 1,335 companies to participate in the survey.
"Appian's employees are the source of our success," said Matt Calkins, CEO of Appian. "We are committed to maintaining a culture of innovation where the best idea wins no matter where it comes from, and where every employee has the right to amaze their peers. Appian employees are extraordinarily talented, and in this kind of environment, talented people do great things."
Appian is ushering in the era of low-code application development. When companies write software on the Appian Platform, it's faster to build, easier to change, more mobile, more portable to the cloud, more integrated, and more secure. By giving companies a better way to write unique software, Appian helps organizations define their own personality, move at the speed of their customers, and shape the meaning of their own brand.
Appian employees are passionate about challenging the status quo and improving the world through great software. Appian's approach gives individuals greater ownership and input into decisions and makes for a more efficient and happier workplace.
This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, statements regarding our commitment to maintaining an innovative culture, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to our ability to maintain our corporate culture and the risks and uncertainties set forth in the "Risk Factors" section of our prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, on May 26, 2017, and subsequent reports that we file with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, we cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. We are under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Appian provides a leading low-code software development platform that enables organizations to rapidly develop powerful and unique applications. The applications created on Appian's platform help companies drive digital transformation and competitive differentiation. For more information, visit www.appian.com.
For Information Contact:
Director, Media Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Appian Corporation via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30 | Pressmeddelande
IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017. A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti
TGS Q2 2017 webcast and teleconference27.7.2017 18:14 | Pressmeddelande
ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-
Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36 | Pressmeddelande
VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850 VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after
Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22 | Pressmeddelande
Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00 | Pressmeddelande
- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia - TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum